| 2025-12-15 |
详情>>
内部人交易：
Mercier Johanna等共交易2笔
|
| 2025-11-07 |
详情>>
股本变动：
变动后总股本124067.96万股
|
| 2025-11-07 |
详情>>
业绩披露：
2025年三季报(累计)每股收益5.08美元,归母净利润63.27亿美元,同比去年增长585.57%
|
| 2025-10-30 |
财报披露：
美东时间 2025-10-30 盘后发布财报
|
| 2025-08-07 |
详情>>
业绩披露：
2025年中报每股收益2.63美元,归母净利润32.75亿美元,同比去年增长228.13%
|
| 2025-05-07 |
详情>>
业绩披露：
2025年一季报每股收益1.06美元,归母净利润13.15亿美元,同比去年增长131.53%
|
| 2025-03-27 |
股东大会：
将于2025-05-07召开股东大会
会议内容 ▼▲
- 1.To elect the nine director nominees named in this Proxy Statement to serve for the next year and until their successors are elected and qualified.
2.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.
3.To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in this Proxy Statement.
|
| 2025-02-28 |
详情>>
业绩披露：
2024年年报每股收益0.38美元,归母净利润4.80亿美元,同比去年增长-91.53%
|
| 2025-02-28 |
详情>>
业绩披露：
2022年年报每股收益3.66美元,归母净利润45.92亿美元,同比去年增长-26.23%
|
| 2024-11-12 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-1.04美元,归母净利润-13.03亿美元,同比去年增长-130.76%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益-2.05美元,归母净利润-25.56亿美元,同比去年增长-224.38%
|
| 2024-08-08 |
详情>>
业绩披露：
2023年中报每股收益1.65美元,归母净利润20.55亿美元,同比去年增长76.70%
|
| 2024-05-08 |
详情>>
业绩披露：
2024年一季报每股收益-3.34美元,归母净利润-41.7亿美元,同比去年增长-512.87%
|
| 2024-03-28 |
股东大会：
将于2024-05-08召开股东大会
会议内容 ▼▲
- 1.To elect the nine director nominees named in this Proxy Statement to serve for the next year and until their successors are elected and qualified.
2.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024.
3.To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.
4.To approve an amendment to our Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation.
5.To vote on a stockholder proposal requesting that the Board include one member from the Company’s non-management employees. AGAINST
6.To vote on a stockholder proposal requesting that the Board issue a report detailing the risks and costs to the Company caused by opposing or otherwise altering Company policy in response to state policies regulating abortion, and detailing any strategies beyond litigation and legal compliance that the Company may deploy to minimize or mitigate these risks. AGAINST
7.To vote on a stockholder proposal requesting that the Board adopt a policy requiring the Company’s named executive officers to retain at least 25% of net-after tax shares of stock acquired through equity pay programs until reaching normal retirement age (at least age 60). AGAINST
8.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2024-02-23 |
详情>>
业绩披露：
2023年年报每股收益4.54美元,归母净利润56.65亿美元,同比去年增长23.37%
|
| 2023-11-07 |
详情>>
业绩披露：
2023年三季报(累计)每股收益3.39美元,归母净利润42.36亿美元,同比去年增长43.50%
|
| 2023-03-23 |
股东大会：
将于2023-05-03召开股东大会
会议内容 ▼▲
- 1.To elect the nine director nominees named in this Proxy Statement to serve for the next year and until their successors are elected and qualified.
2.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.
3.To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.
4.To approve, on an advisory basis, the frequency of future advisory stockholder votes on executive compensation.
5.To approve an amendment and restatement of the Gilead Sciences, Inc. Employee Stock Purchase Plan and the Gilead Sciences, Inc. International Employee Stock Purchase Plan.
6.To vote on a stockholder proposal, if properly presented at the meeting, requesting the Board implement a process to nominate at least one more candidate than the number of directors to be elected.
7.To vote on a stockholder proposal, if properly presented at the meeting, requesting the Board amend the company governing documents to give street name shares and non-street name shares an equal right to call a special stockholder meeting.
8.To vote on a stockholder proposal, if properly presented at the meeting, requesting a report on a process by which the impact of extended patent exclusivities on product access would be considered in deciding whether to apply for secondary and tertiary patents.
|
| 2023-03-23 |
股东大会：
将于2023-05-03召开股东大会
会议内容 ▼▲
- 1.To elect the nine director nominees named in this Proxy Statement to serve for the next year and until their successors are elected and qualified.
2.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.
3.To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.
4.To approve, on an advisory basis, the frequency of future advisory stockholder votes on executive compensation.
5.To approve an amendment and restatement of the Gilead Sciences, Inc. Employee Stock Purchase Plan and the Gilead Sciences, Inc. International Employee Stock Purchase Plan.
6.To vote on a stockholder proposal, if properly presented at the meeting, requesting the Board implement a process to nominate at least one more candidate than the number of directors to be elected.
7.To vote on a stockholder proposal, if properly presented at the meeting, requesting the Board amend the company governing documents to give street name shares and non-street name shares an equal right to call a special stockholder meeting.
8.To vote on a stockholder proposal, if properly presented at the meeting, requesting a report on a process by which the impact of extended patent exclusivities on product access would be considered in deciding whether to apply for secondary and tertiary patents.
|
| 2022-03-24 |
股东大会：
将于2022-05-04召开股东大会
会议内容 ▼▲
- 1.To elect the nine director nominees named in this Proxy Statement to serve for the next year and until their successors are elected and qualified.
2.To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022.
3.To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.
4.To approve the Gilead Sciences, Inc. 2022 Equity Incentive Plan.
5.To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board adopt a policy that the Chairperson of the Board of Directors be an independent director.
6.To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board include one member from Gilead’s non-management employees.
7.To vote on a stockholder proposal, if properly presented at the meeting, requesting a 10% threshold to call a special stockholder meeting.
8.To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board publish a third-party review of Gilead’s lobbying activities.
9.To vote on a stockholder proposal, if properly presented at the meeting, requesting a Board report on oversight of risks related to anticompetitive practices.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-03-31 |
股东大会：
将于2021-05-12召开股东大会
会议内容 ▼▲
- 1.to elect the nine director nominees named in this Proxy Statement to serve for the next year and until their successors are elected and qualified;
2.to ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021;
3.to approve, on an advisory basis, the compensation of our Named Executive Officers as presented in this Proxy Statement;
4.to vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board adopt a policy that the Chairperson of the Board of Directors be an independent director.
|
| 2020-04-29 |
复牌提示：
2020-04-29 08:25:07 停牌，复牌日期 2020-04-29 09:00:00
|
| 2020-03-24 |
股东大会：
将于2020-05-06召开股东大会
会议内容 ▼▲
- 1.To elect the eight director nominees named in this Proxy Statement to serve for the next year and until their successors are elected and qualified.
2.To ratify the selection of Ernst & Young LLP by the Audit Committee of the Board of Directors as the independent registered public accounting firm of Gilead for the fiscal year ending December 31, 2020.
3.To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.
4.To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board adopt a policy that the Chairperson of the Board of Directors be an independent director.
5.To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board eliminate the ownership threshold for stockholders to request a record date to take action by written consent.
6.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2020-02-03 |
除权日：
美东时间 2020-03-12 每股派息0.68美元
|
| 2019-10-23 |
除权日：
美东时间 2019-12-12 每股派息0.63美元
|
| 2019-07-29 |
除权日：
美东时间 2019-09-12 每股派息0.63美元
|
| 2019-05-01 |
除权日：
美东时间 2019-06-13 每股派息0.63美元
|
| 2019-03-25 |
股东大会：
将于2019-05-08召开股东大会
会议内容 ▼▲
- 1.To elect nine directors to serve for the next year and until their successors are elected and qualified.
2.To ratify the selection of Ernst & Young LLP by the Audit Committee of the Board of Directors as the independent registered public accounting firm of Gilead for the fiscal year ending December 31, 2019.
3.To approve an amendment to Gilead’s Restated Certificate of Incorporation to allow stockholders to act by written consent.
4.To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.
5.To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board adopt a policy that the Chairperson of the Board of Directors be an independent director.
6.To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board issue a report describing how Gilead plans to allocate tax savings as a result of the Tax Cuts and Jobs Act.
7.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2019-02-01 |
除权日：
美东时间 2019-03-14 每股派息0.63美元
|
| 2018-10-24 |
除权日：
美东时间 2018-12-13 每股派息0.57美元
|
| 2018-07-24 |
除权日：
美东时间 2018-09-13 每股派息0.57美元
|
| 2018-04-30 |
除权日：
美东时间 2018-06-14 每股派息0.57美元
|
| 2018-03-26 |
股东大会：
将于2018-05-09召开股东大会
会议内容 ▼▲
- 1.to elect nine directors to serve for the next year and until their successors are elected and qualified;
2.to ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018;
3.to approve, on an advisory basis, the compensation of our Named Executive Officers as presented in this Proxy Statement;
4.to vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board adopt a policy that the Chairman of the Board of Directors be an independent director;
5.to vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board take steps to permit stockholder action by written consent.
|
| 2018-02-06 |
除权日：
美东时间 2018-03-15 每股派息0.57美元
|
| 2017-10-26 |
除权日：
美东时间 2017-12-14 每股派息0.52美元
|
| 2017-07-25 |
除权日：
美东时间 2017-09-14 每股派息0.52美元
|
| 2017-05-01 |
除权日：
美东时间 2017-06-14 每股派息0.52美元
|
| 2017-03-27 |
股东大会：
将于2017-05-10召开股东大会
会议内容 ▼▲
- 1. To elect nine directors to serve for the next year and until their successors are elected and qualified.
2. To ratify the selection of Ernst & Young LLP by the Audit Committee of the Board of Directors as the independent registered public accounting firm of Gilead for the fiscal year ending December 31, 2017.
3. To approve a restatement of the Gilead Sciences, Inc. 2004 Equity Incentive Plan.
4. To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.
5. To vote, on an advisory basis, as to the frequency with which executive compensation will be subject to future advisory stockholder votes.
6. To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board take steps to permit stockholder action by written consent.
7. To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board adopt a policy that the Chairman of the Board of Directors be an independent director.
8. To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2017-02-07 |
除权日：
美东时间 2017-03-14 每股派息0.52美元
|
| 2016-11-01 |
除权日：
美东时间 2016-12-13 每股派息0.47美元
|
| 2016-07-25 |
除权日：
美东时间 2016-09-14 每股派息0.47美元
|
| 2016-04-28 |
除权日：
美东时间 2016-06-14 每股派息0.47美元
|
| 2016-03-28 |
股东大会：
将于2016-05-11召开股东大会
会议内容 ▼▲
- 1. To elect nine directors to serve for the next year and until their successors are elected and qualified.
2. To ratify the selection of Ernst & Young LLP by the Audit Committee of the Board of Directors as the independent registered public accounting firm of Gilead for the fiscal year ending December 31, 2016.
3. To approve the Amended and Restated Gilead Sciences, Inc. Code Section 162(m) Bonus Plan.
4. To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.
5. To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board take steps to permit stockholder action by written consent.
6. To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2016-02-02 |
除权日：
美东时间 2016-03-14 每股派息0.43美元
|
| 2015-10-27 |
除权日：
美东时间 2015-12-14 每股派息0.43美元
|
| 2015-07-28 |
除权日：
美东时间 2015-09-14 每股派息0.43美元
|
| 2015-04-30 |
除权日：
美东时间 2015-06-12 每股派息0.43美元
|